1 BTC
=
- USD
Soleno Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Soleno Therapeutics, Inc. Common Stock
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
Market Statistics
Trading Metrics
How to Buy SLNO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SLNO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe Portnoy Law Firm has announced a class action lawsuit on behalf of Soleno Therapeutics investors who purchased securities between March 6, 2025 and November 4, 2025. The lawsuit alleges that Soleno concealed significant safety risks related to its lead drug DCCR, including excess fluid retention issues discovered in Phase 3 trials. The stock declined 27% on November 4, 2025 following disclosure of commercial disruption and a patient death, with investors having until May 5, 2026 to file a lead plaintiff motion.
A class action lawsuit has been filed against Soleno Therapeutics for allegedly making false statements and concealing safety concerns regarding its DCCR drug candidate for Prader-Willi syndrome treatment. The complaint alleges the company downplayed evidence of fluid retention issues in clinical trials and misrepresented the drug's commercial viability. Investors who purchased shares between March 26, 2025 and November 4, 2025 can apply to be lead plaintiff by May 5, 2026.
A securities class action lawsuit has been filed against Soleno Therapeutics regarding alleged false and misleading statements about safety concerns with its DCCR drug candidate for Prader-Willi syndrome. The lawsuit claims the company downplayed evidence of fluid retention issues in clinical trials and concealed materially greater safety risks, leading to lower commercial viability. Investors who purchased stock between March 26, 2025 and November 4, 2025 may be eligible for compensation, with a lead plaintiff deadline of May 5, 2026.
A class action lawsuit has been filed against Soleno Therapeutics, Inc. alleging that the company failed to disclose significant safety concerns related to its DCCR drug candidate, including excess fluid retention issues in clinical trials. The lawsuit claims these undisclosed risks materially reduced the drug's commercial viability and posed greater safety risks than disclosed to investors who purchased securities between March 26, 2025 and November 4, 2025.
A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.
